FDMT

8.39

2.63% 0.215

Dopo l'orario di chiusura: 8.39

4 D Molecular Therapeutics Inc (FDMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$8.175

Aprire:

$8.18

Volume 24 ore:

638.25K

Relative Volume:

0.88

Capitalizzazione di mercato:

$436.02M

Reddito:

$20.72M

Utile/perdita netta:

$-100.84M

Rapporto P/E:

-2.5579

EPS:

-3.28

Flusso di cassa netto:

$-78.56M

1 W Prestazione:

+2.32%

1M Prestazione:

-15.85%

6M Prestazione:

-68.20%

1 anno Prestazione:

-27.67%

Intervallo 1D:

$8.03

$8.44

Intervallo di 1 settimana:

$7.975

$8.44

Portata 52W:

$7.90

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Nome

4 D Molecular Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

(510) 505-2680

Indirizzo

5858 HORTON STREET #455, EMERYVILLE

Dipendente

201

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

FDMT's Discussions on Twitter

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-07	Ripresa	Goldman	Buy
2023-10-26	Iniziato	RBC Capital Mkts	Outperform
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-10-18	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-07-05	Iniziato	Chardan Capital Markets	Buy
2023-01-30	Iniziato	BMO Capital Markets	Outperform
2022-11-18	Iniziato	H.C. Wainwright	Buy
2022-11-15	Aggiornamento	Goldman	Neutral → Buy
2022-08-12	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Iniziato	Jefferies	Buy
2022-01-04	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	BofA Securities	Buy
2021-01-05	Iniziato	Evercore ISI	Outperform
2021-01-05	Iniziato	Goldman	Neutral

Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

02:11 AM

Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com

02:11 AM

Oct 30, 2024

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR

Oct 29, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat

Oct 29, 2024

Oct 27, 2024

Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Oct 27, 2024

Oct 25, 2024

Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan

Oct 25, 2024

Oct 23, 2024

nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Oct 23, 2024

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Oct 22, 2024

Oct 18, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia

Oct 18, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 18, 2024

Oct 17, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India

Oct 17, 2024

Oct 16, 2024

Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe

Oct 16, 2024

Oct 14, 2024

Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily

Oct 14, 2024